The Successful Sequential Use of Plerixafor and Eltrombopag For Hematopoietic Cell Transplantation in a Child With High-risk Neuroblastoma. Issue 7 (October 2020)

• Record Type: Journal Article
• Authors: Marjanska, Agata; Czyzewski, Krzysztof; Debski, Robert; Krenska, Anna; Wysocki, Mariusz; Styczynski, Jan
• Is Part Of: Journal of pediatric hematology/oncology. Volume 42:Issue 7(2020)
• Publication Date: 2020-10
• Subjects: plerixafor -- eltrombopag -- neuroblastoma; Pediatric hematology -- Periodicals; Tumors in children -- Periodicals; 618.9215
• DOI: 10.1097/MPH.0000000000001551
• Languages: English
• ISSNs: 1077-4114

Abstract

Abstract : High-dose chemotherapy with autologous hematopoietic stem cell transplantation improves event-free survival in patients with high-risk neuroblastoma. However, in heavily pretreated patients, poor marrow function can be an obstacle in the successful proceeding of therapy. Priming with plerixafor plus filgrastim is an option for effective mobilization and collection of stem cells. In addition, thrombopoietin agonist eltrombopag can improve the outcome of posttransplantation thrombocytopenia and poor graft function in the posttransplant setting. We describe a case of a child with high-risk neuroblastoma, for whom plerixafor and eltrombopag were used as an effective and safe supportive therapy.